Our vision

The development of induced pluripotent stem (iPS) cells through cellular reprogramming has led in recent years to a new paradigm in allogeneic cell therapy.

This means that iPS cells can produce billions of differentiated, mature and functional human cells in a standardized and controlled way, for use in a wide range of healthcare applications. These new products represent a major medical achievement.
New-generation allogeneic therapies (cells from an unrelated HLA-compatible donor reinjected into the body of another) have a bright future, with the development of « off-the-shelf » bioproduction strategies, making available cell raw materials that can be used to rapidly treat a large number of patients. They already accounted for 46.8% of cell-based therapies in 2020, and are set for strong growth in the near future. Production technologies permitting !

The amplification of iPS cells on an industrial scale remains a real challenge, and faces a number of difficulties. It requires efficient, reproducible protocols and bioreactors that enable real scalability, from R&D through to regulatory industrial production. It requires innovative solutions and new approaches to manufacturing these « ready-to-use » cellular biomedicines.

Soft Cell Therapeutics offers a disruptive and novel manufacturing process, with significant efficiencies thanks to the improvements implemented, capable of increasing the production of cell therapies, while boosting manufacturing yields and the quality of cultured cells.

Soft Cell Therapeutics offers services based on a disruptive production process that increases the yield and quality of sensitive cells.